BindingDB

null

SMILES C1CN(CCN1)c1ccc2ccccc2n1

InChI Key InChIKey=XRXDAJYKGWNHTQ-UHFFFAOYSA-N

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 50014407

5-hydroxytryptamine receptor 1B(Rattus norvegicus (Rat))
University of Texas

Curated by PDSP K_i Database

BDBM50014407(2-(piperazin-1-yl)quinoline | 2-Piperazin-1-yl-qui...)copy SMILEScopy InChI

Ki: 249nMMore data for this Ligand-Target Pair

PDB Reactome pathway KEGG
UniProtKB/SwissProt
GoogleScholar

Purchase CHEMBL MCE
PC cid PC sid Patents Similars

Details
BindingDB Entry DOI: 10.7270/Q2SJ1J3MPubMed

Targets 25 ▿
- 5-hydroxytryptamine receptor 2A 19
- 5-hydroxytryptamine receptor 2C 15
- 5-hydroxytryptamine receptor 1A 14
- 5-hydroxytryptamine receptor 3A/3B 13
- 5-hydroxytryptamine receptor 1B 10
- 5-hydroxytryptamine receptor 2B 8
- 5-hydroxytryptamine receptor 3A 6
- Sodium-dependent serotonin transporter 5
- Serotonin 2 (5-HT2) receptor 4
- 5-hydroxytryptamine receptor 4 3
- 5-hydroxytryptamine receptor 7 3
- 5-hydroxytryptamine receptor 1D 3
- Neutrophil cytosol factor 1 2
- 5-hydroxytryptamine receptor 5A 2
- D(2) dopamine receptor 2
- 5-hydroxytryptamine receptor 6 2
- 5-hydroxytryptamine receptor 3A/3B/3C/3D/3E 2
- Solute carrier family 22 member 1 1
- 5-hydroxytryptamine receptor 1A/1B/1D/1F 1
- Solute carrier family 22 member 2 1
- 5-hydroxytryptamine 1D receptor 1
- Beta-1 adrenergic receptor 1
- D(1A) dopamine receptor 1
- Muscarinic acetylcholine receptor M2 1
- Beta-2 adrenergic receptor 1
- ...
Publications 40 ▿
- J Med Chem 30: 1-12 (1987) 7
- Eur J Pharmacol 168: 387-92 (1989) 7
- NIDA Res Monogr 178: 440-66 (1998) 6
- J Med Chem 40: 3670-8 (1997) 6
- J Med Chem 39: 2068-80 (1996) 6
- J Med Chem 42: 1556-75 (1999) 6
- J Med Chem 40: 1808-19 (1997) 6
- J Med Chem 41: 728-41 (1998) 6
- J Med Chem 38: 2692-704 (1995) 5
- J Med Chem 52: 6946-50 (2009) 4
- J Med Chem 46: 2795-812 (2003) 4
- Neuropharmacology 33: 275-317 (1994) 4
- J Med Chem 52: 3548-62 (2009) 4
- Synapse 35: 144-50 (2000) 4
- Br J Pharmacol 128: 13-20 (1999) 3
- Naunyn Schmiedebergs Arch Pharmacol 370: 114-23 (2004) 3
- Proc Natl Acad Sci U S A 89: 3630-4 (1992) 3
- Life Sci 33: 2011-6 (1983) 3
- J Med Chem 33: 1594-600 (1990) 3
- Nature 305: 140-2 (1983) 2
- J Pharmacol Exp Ther 276: 720-7 (1996) 2
- J Med Chem 33: 3176-81 (1991) 2
- J Med Chem 42: 4362-79 (1999) 2
- J Neurosci 9: 3482-90 (1989) 2
- Eur J Med Chem 49: 200-10 (2012) 2
- J Pharmacol Exp Ther 260: 1361-5 (1992) 2
- J Biol Chem 268: 18200-4 (1993) 2
- J Med Chem 63: 1156-1177 (2020) 2
- Ann N Y Acad Sci 861: 140-5 (1998) 2
- Synapse 25: 137-46 (1997) 1
- J Med Chem 50: 4616-29 (2007) 1
- J Med Chem 56: 3446-55 (2013) 1
- Bioorg Med Chem Lett 10: 1559-62 (2000) 1
- J Med Chem 33: 3020-3 (1990) 1
- J Med Chem 41: 311-7 (1998) 1
- Biochem Pharmacol 45: 375-83 (1993) 1
- J Med Chem 29: 2375-80 (1986) 1
- J Med Chem 39: 4017-26 (1996) 1
- J Neurochem 66: 47-56 (1996) 1
- J Pharmacol Exp Ther 260: 614-26 (1992) 1
Institutions 29 ▿
- [Universit£ di Siena] 23
- [Universit£ de Caen, Virginia Commonwealth University] 12
- [Universit£ de Caen, Virginia Commonwealth University] 12
- [TBA, European Research Centre for Drug Discovery and Development] 8
- [TBA, European Research Centre for Drug Discovery and Development] 8
- [SRI International, Albany Medical College] 6
- [SRI International, Albany Medical College] 6
- [University of Alberta, University of Toronto] 4
- [University of Alberta, University of Toronto] 4
- [Vernalis Research, Synaptic Pharmaceutical Corporation, Merrell Dow Research Institute, University of Copenhagen, Cerebrus Ltd] 3
- [Vernalis Research, Synaptic Pharmaceutical Corporation, Merrell Dow Research Institute, University of Copenhagen, Cerebrus Ltd] 3
- [Vernalis Research, Synaptic Pharmaceutical Corporation, Merrell Dow Research Institute, University of Copenhagen, Cerebrus Ltd] 3
- [Vernalis Research, Synaptic Pharmaceutical Corporation, Merrell Dow Research Institute, University of Copenhagen, Cerebrus Ltd] 3
- [Vernalis Research, Synaptic Pharmaceutical Corporation, Merrell Dow Research Institute, University of Copenhagen, Cerebrus Ltd] 3
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [National Institute of Neurological Disorders and Stroke, Universita' degli Studi di Salerno, Stanford University, Lilly Research Laboratories, INSERM U. 114, National Medicines Institute, Stanford University , Eli Lilly and Company] 2
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
- [Pfizer Central Research, University of Texas, University of Washington, Universit£ Louis Pasteur, Inha University, Heptares Therapeutics Ltd., Janssen Research Foundation] 1
Affinity: 0.45 to 1.4E+6 nM▿
- Ki 98
- IC50 19
- Kd 3
- EC50 1
- Affinity ≤ nM
Xtal structures: 0
Docked structures: 0
Catalog Cmpds: 1